[HTML][HTML] Advanced Glycation End-Products Acting as Immunomodulators for Chronic Inflammation, Inflammaging and Carcinogenesis in Patients with Diabetes and …

CY Shen, CH Lu, CF Cheng, KJ Li, YM Kuo, CH Wu… - Biomedicines, 2024 - mdpi.com
Increased production of advanced glycation end products (AGEs) among reducing sugars
(glucose, fructose, galactose, or ribose) and amino acids/proteins via non-enzymatic …

Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical …

A Natalicchio, N Marrano, M Montagnani… - Journal of …, 2024 - Springer
Background: Increasing evidence suggests that diabetes increases the risk of develo**
different types of cancer. Hyperinsulinemia, hyperglycemia and chronic inflammation …

Emerging Therapeutics targeting cellular stress pathways to mitigate end-organ damage in type 1 diabetes

TA Addissouky - Avicenna Journal of Medical Biochemistry, 2024 - ajmb.umsha.ac.ir
Abstract Type 1 diabetes (T1D) is an autoimmune disease characterized by insulin
deficiency and impaired glucose regulation. While daily insulin therapy is life-saving, many …

Exploratory risk prediction of type II diabetes with isolation forests and novel biomarkers

H Yousef, SF Feng, HF Jelinek - Scientific Reports, 2024 - nature.com
Type II diabetes mellitus (T2DM) is a rising global health burden due to its rapidly increasing
prevalence worldwide, and can result in serious complications. Therefore, it is of utmost …

Epigenetic mechanisms in cardiovascular complications of diabetes: towards future therapies

G Damiano, R Rinaldi, A Raucci, C Molinari, A Sforza… - Molecular …, 2024 - Springer
The pathophysiological mechanisms of cardiovascular disease and microvascular
complications in diabetes have been extensively studied, but effective methods of …

A Narrative Review: Relationship Between Glycemic Variability and Emerging Complications of Diabetes Mellitus

X Wang, Y Cao - Biomolecules, 2025 - mdpi.com
A growing body of evidence emphasizes the role of glycemic variability (GV) in the
development of conventional diabetes-related complications. Furthermore, advancements in …